-
Tetramethylrhodamine ethyl ester perchlorate Assays
2026-09-08
Tetramethylrhodamine ethyl ester perchlorate enables live-cell measurement of mitochondrial membrane potential across microscopy and flow cytometry workflows. This guide connects practical TMRE optimization with a recent trichothecene hepatotoxicity model, helping researchers distinguish mitochondrial depolarization from broader oxidative-stress signals.
-
IEM 1460 AMPA Receptor Blocker Workflows
2026-09-07
IEM 1460 enables controlled AMPA receptor inhibition for experiments spanning fast synaptic signaling, excitotoxicity, and neuronal survival. This practical guide separates product-specific assay workflows from evidence generated with the related dual-target compound IEM-1925, helping researchers design interpretable experiments and troubleshoot variability.
-
Actinomycin D Workflows for RNA Stability
2026-09-05
Actinomycin D enables controlled transcriptional shutoff for mRNA decay, apoptosis induction, and transcriptional stress studies. This guide adapts ActD workflows to circRNA biomarker research, using circUSP10 as a practical bridge between cell-based mechanism and whole-blood assay design.
-
Fingolimod (FTY720) as a Trafficking Control
2026-09-05
Fingolimod (FTY720) offers a rigorous way to dissect lymphocyte trafficking in immune-engineering experiments. This article develops a mechanistic assay framework linking S1P biology, T-cell availability, and magnetically guided CAR-T-mimicking cells without overstating combination evidence.
-
Aclacinomycin A: From rDNA Stress to Translation
2026-09-04
Aclacinomycin A, or Aclarubicin, can serve as a mechanistically rich model of topological stress, DNA damage, proteasome perturbation, and apoptosis. This thought-leadership article connects its dual topoisomerase activity to persistent ribosomal DNA lesions and PML-nucleolar responses, then translates those insights into practical validation strategies for cancer researchers.
-
One-step TUNEL Cy5 Apoptosis Detection Kit Workflow
2026-09-04
Build a reproducible DNA-fragmentation workflow for cultured cells, flow cytometry, and tissue sections using far-red Cy5 detection. The guide connects terminal apoptosis readouts with the KDM3A/METTL16/PDK1 model of tyrosine kinase inhibitor resistance while emphasizing controls, quantitative analysis, and troubleshooting.
-
Bazedoxifene in Osteoporosis Research Workflows
2026-09-03
Bazedoxifene provides a practical way to connect estrogen-receptor pharmacology with transcriptional, cellular, and bone-relevant endpoints. This workflow guide emphasizes dose design, tissue-selective assay choices, formulation control, and troubleshooting for osteoporosis treatment research.
-
WAY-100635 in Pain-Affect Assay Design
2026-09-03
WAY-100635 provides a selective pharmacological control for separating 5-HT1A receptor signaling from broader pain and affective phenotypes. This article develops an assay-design framework linking receptor binding, functional antagonism, behavioral pharmacology, and emerging cannabinoid–serotonin research.
-
Canagliflozin in Reliable Cell Assays
2026-09-02
This scenario-based guide explains how Canagliflozin, SKU A8333, can improve interpretation of cell viability, proliferation, and cytotoxicity experiments by aligning formulation, dose selection, controls, and mitochondrial endpoints. It connects the compound’s SGLT2 potency and solvent properties with renal and metabolic disease research evidence.
-
Neomycin Sulfate: From Mechanism to Assay
2026-09-02
Neomycin sulfate is an aminoglycoside antibiotic with unusually diverse effects on RNA, DNA, and ion-channel systems. This guide converts those mechanisms into evidence-aware assay decisions, using microbiome–immune research to explain controls, causality, and cross-domain limitations.
-
Measuring Cancer Drug Responses Beyond Relative Viability
2026-09-01
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measurements capture different relationships between proliferative arrest and cell death. Its central implication for cancer research is methodological: drug-response studies should measure both outcomes and account for their distinct proportions and timing rather than treating a single viability value as a complete response phenotype.
-
Ziprasidone, GOT1, and PDAC Metabolic Reprogramming
2026-08-31
The reference study identifies ziprasidone as a noncompetitive inhibitor of GOT1, a metabolic enzyme that supports glutamine-derived redox maintenance in pancreatic ductal adenocarcinoma. By combining enzyme assays, metabolomics, cellular phenotyping, genetic knockdown, and xenograft experiments, the authors connect GOT1 inhibition with disrupted glutamine metabolism, oxidative imbalance, reduced tumor-cell proliferation, and apoptosis.
-
Lipid Peroxidation (MDA) Assay Kit Workflow
2026-08-31
Build a practical lipid peroxidation workflow around MDA quantification in cells, tissues, plasma, serum, and urine. The kit’s dual absorbance and fluorescence readouts make it useful for connecting bulk oxidative damage with ferroptosis-focused experiments such as doxorubicin-induced liver injury.
-
CB-5083: Selective p97 Inhibitor Guide
2026-08-30
CB-5083 is an orally bioavailable p97 inhibitor that competes with ATP at the second p97 ATPase domain. Product and peer-reviewed evidence connect p97 inhibition with protein homeostasis disruption, unfolded protein response activation, cancer cell apoptosis induction, and tumor growth inhibition in xenograft models.
-
Prednisolone in Glucocorticoid Signaling Research
2026-08-29
Prednisolone is a practical synthetic glucocorticoid control for separating glucocorticoid receptor activity, inflammation modulation, and immune-cell phenotypes from targeted protein degradation. This workflow explains how to use it alongside ERAD-engaging chimera experiments without incorrectly treating it as the desonide-based degradation warhead reported in the reference study.